Amolyt Pharma

Amolyt Pharma develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Its ambition is to become a leading company in rare diseases with operations in both Europe and the US to support the global development of products. Amolyt Pharma is building an innovative and balanced portfolio of products targeting significant unmet medical needs. Its first two assets are AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for treating syndromes of severe insulin resistance.